Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

被引:78
|
作者
Varga, Zsuzsanna [1 ]
Noske, Aurelia [1 ]
Ramach, Constanze [1 ,2 ]
Padberg, Barbara [1 ,3 ]
Moch, Holger [1 ]
机构
[1] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland
[2] Cty Hosp St Gallen, Inst Pathol, St Gallen, Switzerland
[3] Cty Hosp Aarau, Inst Pathol, Aarau, Switzerland
关键词
HER2; Fluorescence in situ hybridization (FISH); Immunohistochemistry; Breast cancer; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; HIGH CONCORDANCE; AMPLIFICATION; FISH; RECOMMENDATIONS; IMPLEMENTATION; IHC; ER;
D O I
10.1186/1471-2407-13-615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The gold standard of HER2 status assessment in breast cancer is still debated. Immunohistochemistry (IHC) and in-situ technology as fluorescent-labeled methodology (FISH) can be influenced by pre-analytical factors, assay-conditions and interpretation of test results. We retrospectively conducted this quality control study and analyzed HER2 test results in breast cancer within the routine diagnostic service in a single institution over a period of 12 years. We addressed the question how stable and concordant IHC and FISH methods are and whether HER2 positivity rate has changed over this period. Methods: Data of 7714 consecutive HER2-FISH-assays in a period of 12 years (2001-2012) on breast cancer biopsies and excision specimens were retrospectively analyzed. From 2001 to 2004, FISH tests were performed from all cases with IHC score 3+ and 2+ (and in some tumors with IHC score 1+ and 0). From 2005-2010, HER2 status was only determined by FISH. From 2011-2012, all breast carcinomas were analyzed by both IHC and FISH. Scoring and cut-off-definition were done according to time-current ASCO-CAP and FDA-guidelines. Results: Between 2001-2004, IHC score 3+ was diagnosed in 22% of cases, 69% of these 3+ cases were amplified by FISH. 6% of IHC score 0/1+ cases were amplified by FISH. There was a mean amplification rate of 15.8% (range 13-19%) using FISH only HER2-assays (2005-2010). Starting 2008, a slight drop in the amplification rate from 17% to 14% was noticed due to the modified ASCO-criteria in 2007. From 2011-2012, 12% of cases were 3+ by IHC, 84% of them were amplified by FISH. Less than 1% of IHC score 0/1+ cases were amplified by FISH. Concordance between FISH and IHC increased from 83% to 97%. Conclusions: Our quality control study demonstrates that HER2 positivity rate remained stable by FISH-technology but showed a significant variation by IHC over the analyzed 12 years. Improvement in concordance rate was due to standardization of pre-analytical factors, scoring and interpretation.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study
    Zsuzsanna Varga
    Aurelia Noske
    Constanze Ramach
    Barbara Padberg
    Holger Moch
    BMC Cancer, 13
  • [2] HER2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization
    Shirsat, Hemlata S.
    Epari, Sridhar
    Shet, Tanuja
    Bagal, Rajani
    Hawaldar, Rohini
    Desai, Sangeeta B.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2012, 55 (02) : 175 - 179
  • [3] Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast - A single institution experience
    Tubbs, Raymond R.
    Hicks, David G.
    Cook, James
    Downs-Kelly, Erinn
    Pettay, James
    Hartke, Mary Beth
    Hood, LaShonda
    Neelon, Rosemary
    Myles, Jonathan
    Budd, George Thomas
    Moore, Halle C.
    Andresen, Steve
    Crowe, Joseph P.
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2007, 16 (04) : 207 - 210
  • [4] Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
    Vogel, Ulrich F.
    DIAGNOSTIC PATHOLOGY, 2010, 5 : 50
  • [5] Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
    Ulrich F Vogel
    Diagnostic Pathology, 5
  • [6] Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer
    Tseng, Yu-Fen
    Li, Yu-Chia
    Lee, Yi-Hsuan
    Hu, Hsiang-We
    Zhang, Man-San
    Hung, Tze-Chun
    Lien, Huang-Chun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (03) : e48 - e56
  • [7] The Assessment of HER2 Gene Status by Fluorescence In Situ Hybridization in Invasive Breast Carcinomas With Equivocal HER2 Immunostaining: Experience From a Single Institution
    Efared, Boubacar
    Sidibe, Ibrahim S.
    Gamrani, Sana
    El Otmani, Ihsane
    Erregad, Fatimazahra
    Hammas, Nawal
    Bennis, Sanae
    Chbani, Laila
    El Fatemi, Hinde
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2018, 26 (07) : 593 - 599
  • [8] Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China
    Zhao, Bing
    Wang, Yu
    Xu, Hang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (10): : 10459 - 10466
  • [9] Comparison of Fluorescence in situ Hybridization and Immunohistochemistry for Assessment of HER-2 Status in Breast Cancer Patients
    王琳
    王晓蓓
    聂秀
    马玲
    Current Medical Science, 2009, 29 (03) : 354 - 358
  • [10] Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients
    Lin Wang
    Xiaobei Wang
    Xiu Nie
    Ling Ma
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29 : 354 - 358